EPRX Stock Chart & Stats
$7.43
$0.31(5.34%)
At close: 4:00 PM EDT
$7.43
$0.31(5.34%)
Day’s Range― - ―
52-Week Range$5.16 - $9.32
Previous CloseN/A
Volume182.59K
Average Volume (3M)433.86K
Market Cap
$555.59M
Enterprise Value$469.12
Total Cash (Recent Filing)$133.44M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume606,590
30 Day Avg. Volume433,864
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside128.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformA proprietary delivery platform can provide a differentiated foundation across multiple drug candidates and indications. If development succeeds, localized and extended release may support sustained therapeutic activity while potentially reducing systemic exposure, strengthening product positioning.
Low Financial LeverageVery low leverage reduces the immediate burden of debt service and preserves financial flexibility compared with a highly indebted development-stage company. The larger equity base also indicates access to equity capital, supporting continued investment in the pipeline.
Pipeline And Indication BreadthA pipeline addressing multiple inflammatory indications gives Eupraxia more than one potential path to clinical and commercial progress. Diversification across candidates and uses can improve the opportunity set and reduce dependence on a single indication.
Bears Say
Pre-Revenue Business ModelThe company has not yet demonstrated product-market economics because its candidates generate no reported revenue. Until approval and commercialization occur, operating performance depends on development progress and access to external capital rather than recurring customer sales.
Widening Net LossesLosses are increasing rather than stabilizing as the company advances its development programs, indicating a heavier operating cost base without offsetting revenue. Persistent and widening losses can accelerate equity erosion and increase dependence on successful pipeline execution.
Increasing Cash BurnNegative operating and free cash flow show that reported losses are translating into substantial real cash outflows. With burn increasing, Eupraxia will likely require continued financing to fund operations until products generate revenue, creating ongoing capital-raising exposure.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $5.16 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is $555.59M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 53 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -$0.221 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.003.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.221 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went down -3.284%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (128.80% Upside)
$17.00 (128.80% Upside)
Blogger Sentiment
Bullish
EPRX Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $150.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(128.80% Upside)
Technical Analysis
Ownership Overview
10.59% Insiders
0.03% Mutual Funds
26.14% Other Institutional Investors
63.10% Public Companies and
Individual Investors